F
Frederik Barkhof
Researcher at University College London
Publications - 1637
Citations - 123254
Frederik Barkhof is an academic researcher from University College London. The author has contributed to research in topics: Multiple sclerosis & Medicine. The author has an hindex of 154, co-authored 1449 publications receiving 104982 citations. Previous affiliations of Frederik Barkhof include Vanderbilt University Medical Center & IAC.
Papers
More filters
Journal ArticleDOI
Consistent resting-state networks across healthy subjects
Jessica S. Damoiseaux,Serge A.R.B. Rombouts,Frederik Barkhof,Philip Scheltens,Cornelis J. Stam,Stephen M. Smith,Christian F. Beckmann +6 more
TL;DR: Findings show that the baseline activity of the brain is consistent across subjects exhibiting significant temporal dynamics, with percentage BOLD signal change comparable with the signal changes found in task-related experiments.
Journal ArticleDOI
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
Alan J. Thompson,Brenda Banwell,Frederik Barkhof,Frederik Barkhof,William M. Carroll,Timothy Coetzee,Giancarlo Comi,Jorge Correale,Franz Fazekas,Massimo Filippi,Mark S. Freedman,Kazuo Fujihara,Steven L. Galetta,Hans-Peter Hartung,Ludwig Kappos,Fred D. Lublin,Ruth Ann Marrie,Aaron E. Miller,David Miller,Xavier Montalban,Xavier Montalban,Ellen M. Mowry,Per Soelberg Sørensen,Mar Tintoré,Anthony Traboulsee,Maria Trojano,Bernard M. J. Uitdehaag,Sandra Vukusic,Sandra Vukusic,Emmanuelle Waubant,Brian G. Weinshenker,Stephen C. Reingold,Jeffrey A. Cohen +32 more
TL;DR: The 2017 McDonald criteria continue to apply primarily to patients experiencing a typical clinically isolated syndrome, define what is needed to fulfil dissemination in time and space of lesions in the CNS, and stress the need for no better explanation for the presentation.
Journal ArticleDOI
Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration
Joanna M. Wardlaw,Eric E. Smith,Geert J. Biessels,Charlotte Cordonnier,Franz Fazekas,Richard Frayne,Richard I. Lindley,John T. O'Brien,Frederik Barkhof,Oscar R. Benavente,Sandra E. Black,Carol Brayne,Monique M.B. Breteler,Hugues Chabriat,Charles DeCarli,Frank-Erik de Leeuw,Fergus N. Doubal,Marco Duering,Nick C. Fox,Steven M. Greenberg,Vladimir Hachinski,Ingo Kilimann,Vincent Mok,Robert J. van Oostenbrugge,Leonardo Pantoni,Oliver Speck,Blossom C. M. Stephan,Stefan J. Teipel,Anand Viswanathan,David J. Werring,Christopher Chen,Colin Smith,Mark A. van Buchem,Bo Norrving,Philip B. Gorelick,Martin Dichgans +35 more
TL;DR: This Position Paper summarises the main outcomes of this international effort to provide the STandards for ReportIng Vascular changes on nEuroimaging (STRIVE).
Journal ArticleDOI
Defining the clinical course of multiple sclerosis: The 2013 revisions
Fred D. Lublin,Stephen C. Reingold,Jeffrey A. Cohen,Gary Cutter,Per Soelberg Sørensen,Alan J. Thompson,Jerry S. Wolinsky,Laura J. Balcer,Brenda Banwell,Frederik Barkhof,Bruce F. Bebo,Peter A. Calabresi,Michel Clanet,Giancarlo Comi,Robert J. Fox,Mark S. Freedman,Andrew D. Goodman,Matilde Inglese,Ludwig Kappos,Bernd C. Kieseier,John A. Lincoln,Catherine Lubetzki,Aaron E. Miller,Xavier Montalban,Paul O'Connor,John Petkau,Carlo Pozzilli,Richard A. Rudick,Maria Pia Sormani,Olaf Stüve,Emmanuelle Waubant,Chris H. Polman +31 more
TL;DR: Refined descriptors that include consideration of disease activity (based on clinical relapse rate and imaging findings) and disease progression are proposed and strategies for future research to better define phenotypes are outlined.
Journal ArticleDOI
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
Jeffrey A. Cohen,Frederik Barkhof,Giancarlo Comi,Hans Peter Hartung,Bhupendra Khatri,Xavier Montalban,Jean Pelletier,Ruggero Capra,Paolo Gallo,Guillermo Izquierdo,Klaus Tiel-Wilck,Ana de Vera,James Jin,Tracy Stites,Stacy Wu,Shreeram Aradhye,Ludwig Kappos +16 more
TL;DR: This trial showed the superior efficacy of oral fingolimod with respect to relapse rates and MRI outcomes in patients with multiple sclerosis, as compared with intramuscular interferon beta-1a.